ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Debt-to-Equity : 0.01 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is ExpreS2ion Biotech Holding AB Debt-to-Equity?

ExpreS2ion Biotech Holding AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.29 Mil. ExpreS2ion Biotech Holding AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. ExpreS2ion Biotech Holding AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr52.31 Mil. ExpreS2ion Biotech Holding AB's debt to equity for the quarter that ended in Mar. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ExpreS2ion Biotech Holding AB's Debt-to-Equity or its related term are showing as below:

OSTO:EXPRS2' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.31 Med: 0.02 Max: 14.53
Current: 0.01

During the past 11 years, the highest Debt-to-Equity Ratio of ExpreS2ion Biotech Holding AB was 14.53. The lowest was -2.31. And the median was 0.02.

OSTO:EXPRS2's Debt-to-Equity is ranked better than
99.91% of 1066 companies
in the Biotechnology industry
Industry Median: 0.145 vs OSTO:EXPRS2: 0.01

ExpreS2ion Biotech Holding AB Debt-to-Equity Historical Data

The historical data trend for ExpreS2ion Biotech Holding AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ExpreS2ion Biotech Holding AB Debt-to-Equity Chart

ExpreS2ion Biotech Holding AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-2.31

0.02

0.03

ExpreS2ion Biotech Holding AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.03	0.02	0.03	0.03	0.01

Competitive Comparison of ExpreS2ion Biotech Holding AB's Debt-to-Equity

For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ExpreS2ion Biotech Holding AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ExpreS2ion Biotech Holding AB's Debt-to-Equity falls into.

ExpreS2ion Biotech Holding AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ExpreS2ion Biotech Holding AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.275	+	1.436)	/	65.364
	=	0.03

ExpreS2ion Biotech Holding AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.291	+	0)	/	52.308
	=	0.01

ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ExpreS2ion Biotech Holding AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ExpreS2ion Biotech Holding AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

5JD:Germany

Address

c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, S-252 25

Website

https://www.expres2ionbio.com

ExpreS2ion Biotech Holding AB has developed a technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. The company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with research institutions and companies.

ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Headlines

No Headlines